Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia

American Journal of Psychiatry

Volumn 154, Issue 1, 1997, Pages 69-74

  Jacobsen, Leslie K ^a   Frazier, Jean A ^b   Malhotra, Anil K ^b   Karoum, Farouk ^b   McKenna, Kathleen ^b   Gordon, Charles T ^b   Hamburger, Susan D ^b   Lenane, Marge C ^b   Pickar, David ^b   Potter, William Z ^b   Rapoport, Judith L ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; CLOZAPINE; HALOPERIDOL; HOMOVANILLIC ACID; PROLACTIN;

ADOLESCENT; ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHILD CARE; CLINICAL ARTICLE; CLINICAL FEATURE; DOSE RESPONSE; HUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN ANALYSIS; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SCHOOL CHILD; STATISTICAL ANALYSIS;

EID: 0031036165     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.1.69     Document Type: Article

References (44)

1. Narayan M, Srinath S, Andersen GM, Meundi DB: Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry 1993; 33:630-635
2. Andersen GM, Ross DL, Klykylo W, Feibel FC, Cohen DJ: Cere-brospinal fluid indoleacetic acid in autistic subjects. J Autism Dev Disord 1988; 18:259-262
3. Gillberg C, Svennerholm L: CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry 1987; 151:89-94
4. Bowers MB, Heninger GR: Cerebrospinal fluid homovanillic acid patterns during neuroleptic treatment. Psychiatry Res 1981; 4:285-290
5. Post RM, Goodwin FK: Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients. Science 1975; 190:488-489
6. Harnryd C, Bjerkenstedt L, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA: Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand Suppl 1984; 69:75-92
7. Post RM, Fink E, Carpenter WT, Goodwin FK: Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry 1975; 32:1063-1069
8. Sharma RP, Javaid JI, Janicak PG, Davis JM, Faull K: Homovanillic acid in the cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment. Biol Psychiatry 1993; 34: 128-134
9. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A, Linnoila M, Paul SM: Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Arch Gen Psychiatry 1986; 43:669-676
10. Bleich A, Brown SL, Kahn R, van Praag HM: The role of serotonin in schizophrenia. Schizophr Bull 1988; 14:297-315
11. van Kammen DP, Peters J, Yao J, van Kammen WB, Neylan T, Shaw D, Linnoila M: Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psychiatry 1990; 47:161-168
12. van Kammen DP, Ågren H, Yao JK, O'Connor DT, Gurklis J, Peters JL: Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia. Am J Psychiatry 1994; 151:379-384
13. Deakin JFW, Slater P, Simpson MDC, Gilchrist AC, Skan WJ, Royston MC, Reynolds GP, Cross AJ: Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989; 52:1781-1786
14. Banki CM, Karmacsi L, Bissette G, Nemeroff CB: Cerebrospinal-fluid neuropeptides: a biochemical subgrouping approach. Biol Psychiatry 1992; 26:37-42
15. Kirch DB, Alexander RC, Suddath RL, Papadopoulos NM, Kaufmann CA, Daniel DG, Wyatt RJ: Blood-CSF barrier permeability and central nervous system immunoglobulin G in schizophrenia. J Neural Transm 1992; 89:219-232
16. Gelernter J, van Kammen DP: Schizophrenia: instability in norepinephrine, serotonin, and gamma-aminobutyric acid systems. Int Rev Neurobiol 1988; 29:309-347
17. Meltzer HY: Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989; 99(suppl):S18-S27
18. Hsiao JK, Colison J, Bartko JJ, Doran AR, Konicki PE, Potter WZ, Pickar D: Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry 1993; 50:606-614
19. Faull KR, King RJ, Berger PA, Barchas JD: Systems theory as a tool in integrating functional interactions among biogenic amines, in Catecholamines, Part B: Neuropharmacology and Central Nervous System - Therapeutic Aspects. Edited by Usdin E, Carlsson A, Dahlström A, Engel J. New York, Alan R Liss Inc, 1984, pp 143-152
20. Pickar D, Owen RR, Litman RE, Konicki PE, Gutierrez R, Rapaport MH: Clinical and biologic response to clozapine in patients with schizophrenia. Arch Gen Psychiatry 1992; 49:345-353
21. Langer G, Sachar EJ, Gruen PH, Halpern FS: Human prolactin responses to neuroleptic drugs correlate with antischizophrenic potency. Nature 1977; 266:639-640
22. Gordon CT, Frazier JA, McKenna K, Giedd J, Zametkin A, Zahn T, Hommer D, Hong W, Kaysen D, Albus KE, Rapoport JL: Childhood-onset schizophrenia: an NIMH study in progress. Schizophr Bull 1994; 20:697-712
23. Szymanski S, Lieberman J, Pollack S, Munne R, Safferman A, Kane J, Kronig M, Cooper T: The dopamine-serotonin relationship in clozapine response. Psychopharmacology (Berl) 1993; 112:585-589
24. Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL: Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch Gen Psychiatry 1993; 50:599-605
25. Meltzer HY, Fang VS: The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 1976; 33: 279-286
26. Meltzer HY, So R, Miller RJ, Fang VS: Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of h-spiroperidol in the rat pituitary and striatum with in vivo effects on rat prolactin secretion. Life Sci 1979; 25:573-584
27. Gudelsky GA, Nash JF, Berry SA, Meltzer HY: Basic biology of clozapine: electrophysiological and neuroendocrinological studies. Psychopharmacology (Berl) 1989; 99:S13-S17
28. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL: An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994; 33:658-663
29. Puig-Antich J, Orvaschel H, Tabrizi M, Chambers W: The Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologie Version (Kiddie-SADS-E), 3rd ed. New York, New York State Psychiatric Institute and Yale University School of Medicine, 1980
30. Reich W, Weiner Z: Diagnostic Interview for Children and Adolescents - RC (DSM-III-R Version), Revised Version V-R. St Louis, Washington University, 1988
31. Wechsler D: Wechsler Intelligence Scale for Children - Revised. New York, Psychological Corp, 1974
32. Karoum F: Combined gas chromatography-mass spectrometry in the analysis of biogenic amines in humans, in Neuromethods. Edited by Baker GB, Boulton AA, Baker JM. Clifton, NJ, Humana Press, 1985, pp 305-323
33. Karoum F, Chrapusta S, Egan M: Combined gas chromatography-mass spectrometry for the analysis of central and peripheral biogenic amines, in Methods in Neurotransmitter and Neuropeptide Research. Edited by Parvez SH, Naoi M, Nagatsu T, Parvez S. New York, Elsevier, 1993, pp 127-149
34. Andreasen NC: Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, University of Iowa, 1984
35. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
36. Leckman JF, Cohen DJ, Shaywitz BA, Caparulo BK, Heninger GR, Bowers MB: CSF monoamine metabolites in child and adult psychiatric patients. Arch Gen Psychiatry 1980; 37:677-681
37. Gottfries CG, Gottfries I, Johansson B, Olsson R, Persson T, Roos BE, Sjostrom R: Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex. Neuropharmacology 1971; 10:665-672
38. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Lenane MC, Rapoport JL: Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry (in press)
39. Tietz NW: Clinical Guide to Laboratory Tests. Philadelphia, WB Saunders, 1995
40. Wode-Helgodt B, Fyro B, Gullberg B, Sedvall G: Effects of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta Psychiatr Scand 1977; 56:129-142
41. Ackenheil M: Clozapine - pharmacokinetic investigations and biochemical effects in man. Psychopharmacology (Berl) 1989; 99 (suppl):S32-S37
42. Baldessarini RJ, Huston-Lyons D, Campbell A, Marsh E, Cohen BM: Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br J Psychiatry 1992; 160:12-16
43. Muller N, Ackenheil M: Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology. Schizophr Res 1995; 14:223-228
44. Pickar D, Hsiao JK, Litman RE: Regional brain metabolism as predictors of clozapine response. Clin Neuropharmacol 1992; 15(suppl 1, part A):399A-400A